Leadless pacemaker implant, anticoagulation status, and outcomes: Results from the Micra Transcatheter Pacing System Post-Approval Registry

Published:October 28, 2021DOI:


      Early results from the Micra investigational trial and Micra Post-Approval Registry (PAR) demonstrated excellent safety and device performance; however, outcomes based on anticoagulation (AC) status at implant have not been evaluated.


      The purpose of this study was to report implant characteristics, perforation rate, and vascular-related events based on perioperative oral AC strategy in patients undergoing Micra implant.


      We compared procedure characteristics, major complications, and vascular events, including pericardial effusion, stratified by any adverse event (including major complications, minor complications, and observations) or major complication only according to AC status in the Micra PAR.


      Among 1795 patients with AC status available, 585 were not on AC, 795 had AC interrupted, and 415 had AC continued during Micra implant. Non-AC patients tended to be younger, with less history of atrial fibrillation and chronic obstructive pulmonary disease, and more history of dialysis than interrupted and continued patients. The implant success rate was similar for all groups (99.1%–99.8%). Through 30 days postimplant, the overall major complication rate was 3.1% for the non-AC group, 2.6% for the interrupted group, and 1.5% for the continued group. The combined rate for any vascular or pericardial effusion adverse event did not differ significantly among AC strategies (6.5%, 4.8%, and 3.6%, respectively).


      Implant of Micra seems to be safe and feasible regardless of an interrupted or continued periprocedural oral AC strategy, with no increased risk of perforation or vascular complications.


      To read this article in full you will need to make a payment
      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Birnie D.H.
        • Healey J.S.
        • Wells G.A.
        • et al.
        Pacemaker or defibrillator surgery without interruption of anticoagulation.
        N Engl J Med. 2013; 368: 2084-2093
        • Calkins H.
        • Hindricks G.
        • Cappato R.
        • et al.
        2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.
        Heart Rhythm. 2017; 14: e275-e444
        • Birnie D.H.
        • Healey J.S.
        • Wells G.A.
        • et al.
        Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2).
        Eur Heart J. 2018; 39: 3973-3979
        • Kim J.S.
        • She F.
        • Jongnarangsin K.
        • et al.
        Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation.
        Heart Rhythm. 2013; 10: 483-489
        • Lakkireddy D.
        • Reddy Y.M.
        • Di Biase L.
        • et al.
        Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
        J Am Coll Cardiol. 2014; 63: 982-988
        • Nagao T.
        • Suzuki H.
        • Matsunaga S.
        • et al.
        Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy.
        Europace. 2019; 21: 590-597
        • Reynolds D.
        • Duray G.Z.
        • Omar R.
        • et al.
        A leadless intracardiac transcatheter pacing system.
        N Engl J Med. 2016; 374: 533-541
        • El-Chami M.F.
        • Al-Samadi F.
        • Clementy N.
        • et al.
        Updated performance of the Micra transcatheter pacemaker in the real-world setting: a comparison to the investigational study and a transvenous historical control.
        Heart Rhythm. 2018; 5: 1800-1807
        • El-Chami M.F.
        • Roberts P.R.
        • Kypta A.
        • et al.
        How to implant a leadless pacemaker with a tine-based fixation.
        J Cardiovasc Electrophysiol. 2016; 27: 1495-1501
        • Kiani S.
        • Black G.B.
        • Rao B.
        • et al.
        Outcomes of Micra leadless pacemaker implantation with uninterrupted anticoagulation.
        J Cardiovasc Electrophysiol. 2019; 30: 1313-1318
        • San Antonio R.
        • Chipa-Ccasani F.
        • Apolo J.
        • et al.
        Management of anticoagulation in patients undergoing leadless pacemaker implantation.
        Heart Rhythm. 2019; 16: 1849-1854
        • Roberts P.R.
        • Clementy N.
        • Al Samadi F.
        • et al.
        A leadless pacemaker in the real-world setting: the Micra Transcatheter Pacing System Post-Approval Registry.
        Heart Rhythm. 2017; 14: 1375-1379
        • Kusumoto F.M.
        • Schoenfeld M.H.
        • Barrett C.
        • et al.
        2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society.
        J Am Coll Cardiol. 2018; 74: 932-987
        • Li F.
        Propensity score weighting for causal inference with multiple treatments.
        Ann Appl Stat. 2019; 13: 2389-2415
        • Reddy V.Y.
        • Exner D.V.
        • Cantillon D.J.
        • et al.
        Percutaneous implantation of an entirely intracardiac leadless pacemaker.
        N Engl J Med. 2015; 373: 1125-1135
        • Douketis J.D.
        • Spyropoulos A.C.
        • Kaatz S.
        • et al.
        Perioperative bridging anticoagulation in patients with atrial fibrillation.
        N Engl J Med. 2015; 373: 823-833
        • Sugrue A.
        • Siontis K.C.
        • Piccini J.P.
        • Noseworthy P.A.
        Periprocedural anticoagulation management for atrial fibrillation ablation: current knowledge and future directions.
        Curr Treat Options Cardiovasc Med. 2018; 20: 3